美国安进地舒单抗注射液用药指导

It has a high affinity with RANKL, prevents RANK ligands from activating RANK on the surface of osteoclasts, inhibits osteoclast activation and development, reduces bone resorption, increases bone density and bone strength of both cortical bone and trabecular bone, promotes bone reconstruction, and reduces the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

Amgen Biopharmaceutical Company (Amgen) is the world's leading innovative biopharmaceutical R&D and production company and one of the largest biopharmaceutical companies in the world. The company was founded by scientist George B. It was co-founded in 1980 by Dr. Rathmann, Dr. Joseph Rubinfeld and other venture capitalists. It takes "drug innovation" as its core concept and attaches great importance to the accumulation of R&D capabilities. It has achieved major breakthroughs in the fields of human genome, tumor biology, neuroscience, hematology and other fields. So how to use American Amgen denosumab injection?

Desosumab can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion or intradermal injection. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Nursing mothers: It is not known whether denosumab is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from denosumab in nursing infants, the decision whether to discontinue breastfeeding or discontinue the drug should be made taking into account the importance of the drug to the mother. Based on animal studies in pregnant mice lacking the RANK/RANKL signaling pathway that have shown altered maternal mammary gland maturation, resulting in impaired postpartum lactation, maternal exposure to denosumab during pregnancy may impair mammary gland development and lactation.

Pediatric Use: The safety and effectiveness of denosumab in pediatric patients have not been established. Treatment with denosumab may impair bone growth in children with open growth plates and may inhibit delayed eruption of permanent teeth.

Geriatric Use: In the trial, 1,260 patients (44%) who received denosumab were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients.

A routine oral examination should be performed before starting denosumab treatment, and good oral hygiene should be maintained after treatment is started. If a patient develops osteonecrosis of the jaw, treatment for osteonecrosis of the jaw may worsen the condition, and discontinuation of the medication should be considered at this time.

The above is the usage method, I hope it can help everyone.

Recommended related hot articles: /newsDetail/91197.html